Results 21 to 30 of about 3,441 (189)

Quality by Design-Guided Development of Hydrogel-Forming Microneedles for Transdermal Delivery of Enfuvirtide. [PDF]

ACS Appl Mater Interfaces
Enfuvirtide, the inaugural biomimetic fusion inhibitor of HIV-1, has exhibited remarkable antiviral efficacy when administered in conjunction with an optimized antiretroviral regimen.
Li H, Vora LK, Anjani Q, Abraham AM, Cong Y, Moreno-Castellanos N, Ballana E, Riveira Muñoz E, Nevot M, Donnelly RF.   +9 more
europepmc   +2 more sources

Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals [PDF]

, 2009
BACKGROUND: Enfuvirtide was shown to be highly effective in treatment- experienced patients. Data on discontinuation of enfuvirtide and switch to new antiretroviral drugs are scarce.
Fux, Christoph A., Battegay, Manuel, Fux, Christoph A, Weber, R, Vernazza, P, Cavassini, M., Swiss HIV Cohort Study,, Elzi, L., Cavassini, M, Bernasconi, E, Vernazza, P., Battegay, M., Bernasconi, Enos, Fux, C. A., Weber, R., Elzi, L, Hirschel, Bernard, Kaufmann, G., Fux, C A, Kaufmann, Gilbert, Elzi, Luigia, Hirschel, B, Vernazza, Pietro, Fux, C.A., Kaufmann, G, Battegay, M, Weber, Rainer, Hirschel, B., Cavassini, Matthias, Bernasconi, E.   +29 more
core   +1 more source

Enfuvirtide-Protoporphyrin IX Dual-Loaded Liposomes: In Vitro Evidence of Synergy against HIV‑1 Entry into Cells [PDF]

, 2019
We have developed a nanocarrier consisting of large unilamellar vesicles (LUVs) for combined delivery of two human immunodeficiency virus type 1 (HIV-1) entry inhibitors, enfuvirtide (ENF) and protoporphyrin IX (PPIX).
Miguel A. R. B. Castanho (7295609), Iris Cadima-Couto (221131), Astrid Walrant (344986), Françoise Illien (8157801), David Andreu (105466), Toni Todorovski (6526019), Ana Salomé Veiga (2054716), Tiago N. Figueira (5782010), Marco M. Domingues (368546), Sandrine Sagan (246380)   +9 more
core   +1 more source

A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. [PDF]

PLoS ONE, 2012
We constructed novel HIV-1 fusion inhibitors that may overcome the current limitations of enfuvirtide, the first such therapeutic in this class. The three prototypes generated by the Dock-and-Lock (DNL) technology to comprise four copies of enfuvirtide ...
Chien-Hsing Chang, Jorma Hinkula, Meiyu Loo, Tina Falkeborn, Rongxiu Li, Thomas M Cardillo, Edmund A Rossi, David M Goldenberg, Britta Wahren   +8 more
doaj   +1 more source

The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype

Retrovirology, 2012
Background Resistance to the fusion inhibitor enfuvirtide (ENF) is achieved by changes in the gp41 subunit of the HIV envelope glycoprotein (Env). Specific ENF-associated mutational pathways correlate with immunological recovery, even after virological ...
Cunyat Francesc, Marfil Silvia, García Elisabet, Svicher Valentina, Pérez-Alvárez Nuria, Curriu Marta, Perno Carlo, Clotet Bonaventura, Blanco Julià, Cabrera Cecilia   +9 more
doaj   +1 more source

The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide [PDF]

, 2010
Mutations that are selected at low frequency and/or reside outside the enfuvirtide target region, amino acid 36-45 of gp41, might still be important determinants for drug resistance.
Vandamme, Anne-Mieke, Dekeersmaeker, Nathalie, Van Laethem, Kristel, Kabeya, Kabamba, Megens, Sarah, De Wit, Stéphane, Balzarini, Jan, Covens, Kris   +7 more
core   +1 more source

Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. [PDF]

PLoS ONE, 2011
The B', CRF07_BC and CRF01_AE are the predominant HIV-1 subtypes in China. It is essential to determine their baseline susceptibility to HIV entry inhibitors before these drugs are used in China.The baseline susceptibility of 14 representative HIV-1 ...
Xiaoling Yu, Lin Yuan, Yang Huang, Weisi Xu, Zhiming Fang, Shuwen Liu, Yiming Shao, Shibo Jiang, Liying Ma   +8 more
doaj   +1 more source

Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic. [PDF]

Microb Biotechnol
Replication cycle of HIV‐1. The scheme provides an overview from virus entry over reverse transcription of viral RNA into viral DNA, provirus DNA integration into the host genome, genome expression by transcription and translation, proteolytic processing of the viral polyproteins, viral maturation to viral release from the cell. The various targets for
Brüssow H.
europepmc   +2 more sources

Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes [PDF]

, 2009
Background: Enfuvirtide is active against isolates from different HIV-1 subtypes. In vitro and in vivo studies reveal that resistance mutations are primarily found within the region spanning amino acid 36-45 of gp41.
Van Wijngaerden, Eric, Eric Van Wijngaerden, Yoeri Schrooten, De Wit, Stéphane, Stéphane De Wit, Covens, Kris, Kristel Van Laethem, Vandamme, Anne-Mieke, Kabamba Kabeya, Dekeersmaeker, Nathalie, Anne-Mieke Vandamme, Van Laethem, Kristel, Kabeya, Kabamba, Kris Covens, Schrooten, Yoeri, Nathalie Dekeersmaeker   +15 more
core   +1 more source

Relapse of Intravenous Drug Use Triggered by Enfuvirtide, a Parenteral Antiretroviral Medication [PDF]

, 2012
Fuzeon (R) (enfuvirtide; Hoffmann-LaRoche, Nutley, NJ) is a parenteral medication prescribed to antiretroviral-experienced HIV patients. Clinicians are frequently concerned when prescribing enfuvirtide to former drug addicts because of the risk of ...
Avelino-Silva, Vivian Iida, Gallafrio Novaes, Christina Terra   +1 more
core   +1 more source